StemCells (STEM) Awarded $20M from California Institute for Regenerative Medicine
Tweet Send to a FriendGet Alerts STEM Hot Sheet
Up)
Trade STEM Now!
StemCells, Inc. (Nasdaq: STEM) announced after the close Thursday that the California Institute for Regenerative Medicine (CIRM) has approved an award to the Company and its collaborators for up to $20 million under CIRM's Disease Team Therapy Development Award program (RFA 10-05).
The award is to fund preclinical development of StemCells' proprietary HuCNS-SC® product candidate (purified human neural stem cells) as a potential treatment for cervical spinal cord injury.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The award is to fund preclinical development of StemCells' proprietary HuCNS-SC® product candidate (purified human neural stem cells) as a potential treatment for cervical spinal cord injury.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Fannie Mae, Freddie Mac Surge as Seriously Delinquent Rate Falls Below 3%
- AMD (AMD) Looks to Outdo Intel (INTC) in Battle of Performance Tablets with Latest SoC Offerings
- InterOil (IOC) Gets Blue Chip 'Stamp of Approval', But Talks Ongoing
Create E-mail Alert Related Categories
Corporate News, Momentum Movers
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
